Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide

References

• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9
   PubMed Web of Science ®Google Scholar
• Khosla S. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 2003;18:1146-9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Cosman F, Eastell R, et al. Goal-directed treatment of osteoporosis. J Bone Miner Res 2013;28:433-8
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42:1246-54
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10
   PubMed Web of Science ®Google Scholar
• Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81
   PubMed Web of Science ®Google Scholar
• Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785-90
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6
   PubMed Web of Science ®Google Scholar
• Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401
   PubMed Web of Science ®Google Scholar
• Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 2004;19:1250-8
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugimoto T, Nakano T, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97:3097-106
   PubMed Web of Science ®Google Scholar
• Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 1996;11:984-6
   PubMed Web of Science ®Google Scholar
• Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167-78
   PubMed Web of Science ®Google Scholar
• Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-61
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010;47:493-502
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Saito M, Marumo K, Kida Y, et al. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 2010;22:2373-83
   PubMed Web of Science ®Google Scholar